Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-03-24

Clinical Trial Update: Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN) [Phase 2]

View source ↗

Summary

Phase 2 study of daxdilimab (HZN-7734) in active proliferative lupus nephritis was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Daxdilimab (HZN-7734) (daxdilimab)

Snippet

Sponsor: Amgen | Conditions: Lupus Nephritis | Phase 2 | Status: TERMINATED | Results posted: 2025-03-24